Biocon Ltd (BOM:532523)

Half Year 2026 Biocon Ltd Earnings Call Transcript

Nov 11, 2025 / 03:30 AM GMT

Release Date Price: ₹406.35 (+5.52%)

Transcript

Key Points

Positve

Biocon Ltd (BOM:532523) reported a strong quarter with double-digit year-on-year growth in both biosimilars and generics.
The company successfully launched multiple biosimilar products, including ustekinumab, aspart, bevacizumab, and aflibacept, with plans for more launches.
Biocon Ltd (BOM:532523) strengthened its balance sheet by settling structured debt obligations, leading to expected annual savings of around 300 crores in interest costs from FY27.
The company entered a strategic partnership with the government of California to supply affordable insulin glargine, expanding its reach to underserved populations.
Biocon Ltd (BOM:532523) recorded improvements in ESG scores, reflecting its commitment to responsible and sustainable growth.

Negative

The CRDMO business reported only a modest 2% year-on-year growth, indicating slower performance compared to other segments.
There are concerns about competitive intensity in the biosimilars market, especially with new players potentially accelerating their development.
The generics business faces pricing pressure, particularly in the statins segment, impacting overall margins.
Despite strong performance, the company still has structured debt with Edelweiss, which is expected to be settled by January.
There is uncertainty regarding the commercialization timeline for certain products like denosumab and bevacizumab, which could impact future revenue.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BION.NS - Biocon Ltd
Half Year 2026 Biocon Ltd Earnings Call
Nov 12, 2025 / 03:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to Biocon Limited's Q2 F 26 earnings conference call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. If you would like to ask a question, please click on the Ask a Question tab. Please note that this conference is being recorded. I now hand the conference over to Mr. Saurav Paliwal from Biocon Investor Relations.

Thank you and over to you, Mr. Paliwal.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Michelle, and good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.